{"id":"daptomycin-up-to-14-days","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Elevated creatine phosphokinase (CPK)"},{"rate":"1-2%","effect":"Muscle pain or myopathy"},{"rate":"1-2%","effect":"Injection site reactions"},{"rate":"1-2%","effect":"Nausea"},{"rate":"1%","effect":"Headache"},{"rate":"1%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4744444","moleculeType":"Unknown","molecularWeight":"1620.69"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daptomycin is a cyclic lipopeptide antibiotic that inserts into the bacterial cell membrane in a calcium-dependent manner. This insertion disrupts the electrochemical gradient across the membrane, causing potassium efflux and depolarization. The resulting loss of membrane potential is bactericidal, making it effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA).","oneSentence":"Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:08.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria"},{"name":"Staphylococcus aureus bacteremia, including right-sided endocarditis"}]},"trialDetails":[{"nctId":"NCT05137119","phase":"PHASE4","title":"Staphylococcus Aureus Network Adaptive Platform Trial","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2022-02-16","conditions":"Staphylococcus Aureus Bacteremia","enrollment":8000},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT00711802","phase":"PHASE4","title":"Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-07-23","conditions":"Skin Diseases, Infectious","enrollment":396},{"nctId":"NCT00102947","phase":"PHASE4","title":"Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2005-01","conditions":"Soft Tissue Infections","enrollment":72},{"nctId":"NCT01184872","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":"Infections","enrollment":120},{"nctId":"NCT00463801","phase":"PHASE4","title":"Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-01","conditions":"Staphylococcal Skin Infections","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"daptomycin (up to 14 days)","genericName":"daptomycin (up to 14 days)","companyName":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death. Used for Complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria, Staphylococcus aureus bacteremia, including right-sided endocarditis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}